These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 37407548)

  • 1. Blood transcriptomic signatures associated with molecular changes in the brain and clinical outcomes in Parkinson's disease.
    Irmady K; Hale CR; Qadri R; Fak J; Simelane S; Carroll T; Przedborski S; Darnell RB
    Nat Commun; 2023 Jul; 14(1):3956. PubMed ID: 37407548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease.
    Kuwabara H; Cumming P; Yasuhara Y; Léger GC; Guttman M; Diksic M; Evans AC; Gjedde A
    J Nucl Med; 1995 Jul; 36(7):1226-31. PubMed ID: 7790948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.
    Rinne JO; Ruottinen H; Bergman J; Haaparanta M; Sonninen P; Solin O
    J Neurol Neurosurg Psychiatry; 1999 Dec; 67(6):737-41. PubMed ID: 10567489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications.
    Kish SJ; Shannak K; Hornykiewicz O
    N Engl J Med; 1988 Apr; 318(14):876-80. PubMed ID: 3352672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data.
    Sawle GV; Playford ED; Burn DJ; Cunningham VJ; Brooks DJ
    Arch Neurol; 1994 Mar; 51(3):237-43. PubMed ID: 8129633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Striatal opioid receptor binding in Parkinson's disease, striatonigral degeneration and Steele-Richardson-Olszewski syndrome, A [11C]diprenorphine PET study.
    Burn DJ; Rinne JO; Quinn NP; Lees AJ; Marsden CD; Brooks DJ
    Brain; 1995 Aug; 118 ( Pt 4)():951-8. PubMed ID: 7655890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum.
    Kaufman MJ; Madras BK
    Synapse; 1991 Sep; 9(1):43-9. PubMed ID: 1796351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Baldwin RM; Zoghbi S; Zea-Ponce Y; Charney DS; van Dyck CH; Hoffer PB; Innis RB
    J Nucl Med; 1997 Sep; 38(9):1453-9. PubMed ID: 9293807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct dopaminergic abnormalities in traumatic brain injury and Parkinson's disease.
    Jenkins PO; Roussakis AA; De Simoni S; Bourke N; Fleminger J; Cole J; Piccini P; Sharp D
    J Neurol Neurosurg Psychiatry; 2020 Jun; 91(6):631-637. PubMed ID: 32381639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
    Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Burn D; Johnson M; Perry RH; McKeith IG; Ballard C; Perry EK
    Brain; 1999 Aug; 122 ( Pt 8)():1449-68. PubMed ID: 10430831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
    Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Onset pattern of nigrostriatal denervation in early Parkinson's disease.
    Pineda-Pardo JA; Sánchez-Ferro Á; Monje MHG; Pavese N; Obeso JA
    Brain; 2022 Apr; 145(3):1018-1028. PubMed ID: 35349639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain.
    Madras BK; Gracz LM; Fahey MA; Elmaleh D; Meltzer PC; Liang AY; Stopa EG; Babich J; Fischman AJ
    Synapse; 1998 Jun; 29(2):116-27. PubMed ID: 9593102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Common gene expression signatures in Parkinson's disease are driven by changes in cell composition.
    Nido GS; Dick F; Toker L; Petersen K; Alves G; Tysnes OB; Jonassen I; Haugarvoll K; Tzoulis C
    Acta Neuropathol Commun; 2020 Apr; 8(1):55. PubMed ID: 32317022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired dual tasking in Parkinson's disease is associated with reduced focusing of cortico-striatal activity.
    Nieuwhof F; Bloem BR; Reelick MF; Aarts E; Maidan I; Mirelman A; Hausdorff JM; Toni I; Helmich RC
    Brain; 2017 May; 140(5):1384-1398. PubMed ID: 28335024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Network degeneration in Parkinson's disease: multimodal imaging of nigro-striato-cortical dysfunction.
    Ruppert MC; Greuel A; Tahmasian M; Schwartz F; Stürmer S; Maier F; Hammes J; Tittgemeyer M; Timmermann L; van Eimeren T; Drzezga A; Eggers C
    Brain; 2020 Mar; 143(3):944-959. PubMed ID: 32057084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of statins on dopamine loss and prognosis in Parkinson's disease.
    Jeong SH; Lee HS; Chung SJ; Yoo HS; Jung JH; Baik K; Lee YH; Sohn YH; Lee PH
    Brain; 2021 Nov; 144(10):3191-3200. PubMed ID: 34347020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
    Morissette M; Morin N; Grégoire L; Rajput A; Rajput AH; Di Paolo T
    Biochem Pharmacol; 2016 Jun; 109():62-69. PubMed ID: 27038656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease.
    Niccolini F; Foltynie T; Reis Marques T; Muhlert N; Tziortzi AC; Searle GE; Natesan S; Kapur S; Rabiner EA; Gunn RN; Piccini P; Politis M
    Brain; 2015 Oct; 138(Pt 10):3003-15. PubMed ID: 26210536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
    J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.